Cardiovascular involvement in patients with systemic sclerosis: Insights from electromechanical characteristics of the heart;Sistemik sklerozlu hastalarda kardiyovasküler tutulum: Kalbin elektromekanik özelliklerinden çıkarsamalar

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 7, 2011, Pages 643-647

  Karabay, Can Yücel ^a   Karaahmet, Tansu ^b   Tigen, Kürşat ^a  

^a Kartal Kosuyolu Training and Research Hospital   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Cardiac involvement of systemic sclerosis; Cardiac magnetic resonance; Doppler echocardiography; Electromechanical properties of the heart

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART ELECTROMECHANICAL PROPERTY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE; HEART SCINTISCANNING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL DISEASE; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SUDDEN DEATH; SYSTEMIC SCLEROSIS; TISSUE DOPPLER IMAGING;

EID: 80054691082     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.170     Document Type: Review

References (53)

1. Olski TM, Hunzelmann N. Immunosuppressive and antifibrotic therapy of systemic sclerosis. Expert Rev Dermatol 2007; 2: 203-15. [CrossRef]
2. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
3. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54. [CrossRef]
4. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
5. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005; 44: 1212-6. [CrossRef]
6. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-5. [CrossRef]
7. Roman MJ, Salmon JE. Cardiovascular manifestations of rheumatologic diseases. Circulation 2007; 116: 2346-55. [CrossRef]
8. Karaahmet T, Tigen K, Gürel E, Taki{dotless}r M, Avci{dotless} A, Çevik C, et al. Impact of systemic sclerosis on electromechanical characteristics of the heart. Heart Vessels 2010; 25: 223-8. [CrossRef]
9. Follansbee WP, Miller TR, Curtiss EI, Orie JE, Bernstein RL, Kiernan JM, et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990; 17: 656-62.
10. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976; 53: 483-90. [CrossRef]
11. Follansbee WP, Curtiss EI, Medsger TA, Steen VD, Uretsky BF, Owens GR, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984; 310: 142-8. [CrossRef]
12. Kahan A, Devaux JY, Amor B, Menkès CJ, Weber S, Nitenberg A, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986; 314: 1397-402. [CrossRef]
13. Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology 2006; 45: 1395-8. [CrossRef]
14. Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005; 64: 1268-73. [CrossRef]
15. Alexander EL, Firestein GS, Weiss JL Heuser RR, Leitl G, Wagner HN Jr, et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986; 105: 661-8.
16. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum 1989; 19: 191-200. [CrossRef]
17. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 1978; 95: 563-9. [CrossRef]
18. Roberts NK, Cabeen WR Jr, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 1981; 94: 38-40. [CrossRef]
19. Kostis JB, Seibold JR, Turkevich D, Masi AT, Grau RG, Medsger TA Jr, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988; 84: 1007-15. [CrossRef]
20. Ferri C, Bernini L, Bongiorni MG, Levorato D, Viegi G, Bravi P, et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum 1985; 28: 1259-66. [CrossRef]
21. Sackner MA, Heinz ER, Steinberg AJ. The heart in scleroderma. Am J Cardiol 1966; 17: 542-59. [CrossRef]
22. Roberts NK, Cabeen WR. Atrioventricular nodal function in progressive systemic sclerosis: electrophysiological and morphological findings. Br Heart J 1980; 44: 529-33. [CrossRef]
23. Follansbee WP, Curtiss EI, Rahko PS, Medsger TA Jr, Lavine SJ, Owens GR, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med 1985; 79: 183-92. [CrossRef]
24. Clements PJ, Furst DE, Cabeen W, Tashkin D, Paulus HE, Roberts N. The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med 1981; 71: 38-46. [CrossRef]
25. Paradiso M, Gabrielli F, Coppotelli L, Aguglia G, Pergolini M, Leonardo M, et al. Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. Int J Cardiol 1996; 53: 171-7. [CrossRef]
26. Paradiso M, Di Franco M, Musca A, Basili S, Riccieri V, Paoletti V, et al. Ventricular late potentials in systemic sclerosis: relationship with skin involvement. J Rheumatol 2002; 29: 1388-92.
27. Sgreccia A, Morelli S, Ferrante L, Perrone C, De Marzio P, De Vincentiis G, et al. QT interval and QT dispersion in systemic sclerosis (scleroderma). J Intern Med 1998; 243: 127-32.
28. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis 2008; 51: 58-73. [CrossRef]
29. Rokas S, Mavrikakis M, Agrios N, Mylonas D, Antoniadou L, Moulopoulos S. Electrophysiologic abnormalities of cardiac function in progressive systemic sclerosis. J Electrocardiol 1996; 29: 17-25. [CrossRef]
30. Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56: 393-4. [CrossRef]
31. Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, et al. Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum 2005; 34: 721-7. [CrossRef]
32. Moyssakis I, Gialafos E, Vassiliou V, Taktikou E, Katsiari C, Papadopoulos DP, et al. Aortic stiffness in systemic sclerosis in increased independently of the extent of skin involvement. Rheumatology 2005; 44: 251-4. [CrossRef]
33. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
34. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-25. [CrossRef]
35. Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J 1992; 56: 983-91. [CrossRef]
36. Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110: 1515-9. [CrossRef]
37. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124: 2098-104. [CrossRef]
38. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24. [CrossRef]
39. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453-9. [CrossRef]
40. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93. [CrossRef]
41. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800. [CrossRef]
42. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93. [CrossRef]
43. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 269-74. [CrossRef]
44. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22. [CrossRef]
45. Hassoun PM. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Resp Med 2009; 3: 187-96. [CrossRef]
46. Gürtner C, Werner RJ, Winten G, Krause BJ, Wendt T, Hör G, et al. Early diagnosis of cardiac involvement in systemic sclerosis by 123I-MIBG neurotransmitter scintigraphy. Nucl Med Commun 1998; 19: 849-57. [CrossRef]
47. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56: 3827-36. [CrossRef]
48. Hirono K, Konishi T, Origasa H, Ichida F, Miyawaki T. Echocardiographic and electrocardiographic analyses of patients with severe motor and intellectual disabilities. Heart Vessels 2009; 24: 46-53. [CrossRef]
49. Meune C, Allanore Y, Pascal O, Devaux JY, Dessault O, Duboc D, et al. Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiography 2005; 6: 351-7. [CrossRef]
50. Mele D, Censi S, La Corte R, Merli E, Lo Monaco A, Locaputo A, et al. Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using Doppler measures of myocardial strain. J Am Soc Echocardiogr 2008; 21: 1257-64. [CrossRef]
51. Karaahmet T, Tigen K, Gürel E, Taki{dotless}r M, Avci{dotless} A, Çevik C, et al. Impact of systemic sclerosis on electromechanical characteristics of the heart. Abstracts of the European Society of Cardiology Congress 2010. 28 August-01 September. Stockholm, Sweden. 2010 p. 453. [CrossRef]
52. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol 2002; 40: 1615-22. [CrossRef]
53. Suffoletto MS, Dohi K, Cannesson M, Saba S, Gorcsan J 3rd. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006; 113: 960-8. [CrossRef]